Studies have shown that in non-small cell lung cancer (NSCLC), the inhibitory immune checkpoint molecule PD-L1 (programmed death receptor-ligand 1) is highly upregulated in tumors at late stages of EMT progression [32]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.